CY1123712T1 - Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας - Google Patents

Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας

Info

Publication number
CY1123712T1
CY1123712T1 CY20201101121T CY201101121T CY1123712T1 CY 1123712 T1 CY1123712 T1 CY 1123712T1 CY 20201101121 T CY20201101121 T CY 20201101121T CY 201101121 T CY201101121 T CY 201101121T CY 1123712 T1 CY1123712 T1 CY 1123712T1
Authority
CY
Cyprus
Prior art keywords
active substance
administration
therapeutic system
layer
transcutaneous therapeutic
Prior art date
Application number
CY20201101121T
Other languages
English (en)
Inventor
Britta Langer
Bjoern Schurad
Heike Prinz
Original Assignee
Luye Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luye Pharma Ag filed Critical Luye Pharma Ag
Publication of CY1123712T1 publication Critical patent/CY1123712T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ένα διαδερμικό θεραπευτικό σύστημα για την χορήγηση μιας δραστικής ουσίας μέσω του δέρματος που είναι κατάλληλο για χρονικό διάστημα εφαρμογής τουλάχιστον τριών ημερών, το οποίο περιλαμβάνει τις τοποθετημένες με την ακόλουθη σειρά μεταξύ τους στοιβάδες: a) μια στοιβάδα επικάλυψης, b) μια στοιβάδα δραστικής ουσίας, η οποία περιλαμβάνει μια πολυμερική μήτρα που περιέχει τη δραστική ουσία, c) μια συγκολλητική στοιβάδα που περιλαμβάνει μια κόλλα επαφής, η οποία αποτελείται από ένα μείγμα από ένα ή περισσότερα πολυισοβουτυλένια και ένα ή περισσότερα πολυβουτένια, και d) μια αφαιρούμενη στοιβάδα.
CY20201101121T 2010-12-14 2020-11-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας CY1123712T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194968.3A EP2468274B1 (de) 2010-12-14 2010-12-14 Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
EP11799413.7A EP2651410B1 (de) 2010-12-14 2011-12-14 Transdermales therapeutisches system zur verabreichung eines wirkstoffs
PCT/EP2011/072812 WO2012080365A1 (de) 2010-12-14 2011-12-14 Transdermales therapeutisches system zur verabreichung eines wirkstoffs

Publications (1)

Publication Number Publication Date
CY1123712T1 true CY1123712T1 (el) 2022-03-24

Family

ID=43836835

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100738T CY1116638T1 (el) 2010-12-14 2015-08-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CY20201101121T CY1123712T1 (el) 2010-12-14 2020-11-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100738T CY1116638T1 (el) 2010-12-14 2015-08-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας

Country Status (25)

Country Link
US (2) US10660863B2 (el)
EP (2) EP2468274B1 (el)
JP (1) JP6043296B2 (el)
KR (1) KR101842309B1 (el)
CN (3) CN103269698B (el)
AU (2) AU2011343363B2 (el)
BR (1) BR112013014616B1 (el)
CA (2) CA3065240C (el)
CY (2) CY1116638T1 (el)
DK (2) DK2468274T3 (el)
EA (1) EA026520B1 (el)
ES (2) ES2545094T3 (el)
HK (1) HK1243336A1 (el)
HR (2) HRP20150881T1 (el)
HU (2) HUE027916T2 (el)
LT (1) LT2651410T (el)
MX (1) MX345344B (el)
MY (1) MY183873A (el)
PL (2) PL2468274T3 (el)
PT (2) PT2468274E (el)
RS (2) RS54173B1 (el)
SI (2) SI2468274T1 (el)
SM (1) SMT201500184B (el)
WO (1) WO2012080365A1 (el)
ZA (1) ZA201303965B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012000369A1 (de) * 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
DE102012016317A1 (de) * 2012-08-14 2014-02-20 Jenabatteries GmbH Redox-Flow-Zelle zur Speicherung elektrischer Energie
EP2884969A1 (en) * 2012-08-15 2015-06-24 Dow Corning Corporation Multi - layer transdermal drug delivery system
WO2014111790A2 (en) * 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US20240082065A1 (en) * 2016-07-08 2024-03-14 Moteah Williams Waterproof and transparent wound barrier and method of manufacturing same
JP6864968B2 (ja) 2016-08-22 2021-04-28 救急薬品工業株式会社 貼付剤
WO2019017266A1 (ja) * 2017-07-19 2019-01-24 帝國製薬株式会社 リバスチグミン含有経皮吸収型製剤
DE102018120506A1 (de) * 2017-10-20 2019-04-25 Amw Gmbh Stabilisiertes transdermales Darreichungssystem
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
BR112020018300A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
CN111885992B (zh) * 2018-05-17 2023-12-08 松下知识产权经营株式会社 生物体贴附用选择性透过膜、透皮吸收套件和美容方法
EP3513965B1 (en) 2018-08-08 2022-05-04 Danapak Flexibles A/S Improved films and laminates for use in packaging reactive compounds
KR20200025883A (ko) 2018-08-31 2020-03-10 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
CN114007595A (zh) * 2019-07-09 2022-02-01 罗曼治疗系统股份公司 包括包含丙烯酸类聚合物的含活性剂层和包含硅酮凝胶粘合剂的皮肤接触层的透皮治疗系统
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
CA2142871A1 (en) * 1992-08-25 1994-03-03 Jesus Miranda Printed transdermal drug delivery device
JPH0912448A (ja) * 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10103860B4 (de) * 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US8252319B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
DE602005021909D1 (de) * 2004-10-21 2010-07-29 Durect Corp Transdermale verabreichungssysteme
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US7943812B2 (en) * 2005-12-30 2011-05-17 Colopast A/S Layered adhesive construct having a mouldable layer as skin contact surface
CN101304735A (zh) * 2006-01-12 2008-11-12 Lts勒曼治疗系统股份公司 用于挥发性和/或热不稳定的物质的经皮治疗体系
RU2428179C2 (ru) * 2006-05-08 2011-09-10 Тейкоку Сейяку Ко., Лтд. Препаративные формы лекарственных средств против слабоумия для чрескожного введения
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20100292660A1 (en) 2007-07-10 2010-11-18 Agis Kydonieus Dermal delivery device with ultrasonic weld
WO2009026135A2 (en) * 2007-08-17 2009-02-26 Alza Corporation Controlled transdermal bisoprolol delivery system
EP2255802B1 (en) * 2008-02-27 2018-01-17 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP2010126450A (ja) * 2008-11-25 2010-06-10 Lintec Corp 経皮吸収貼付剤
PL2515886T3 (pl) * 2009-12-22 2018-08-31 Luye Pharma Ag Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych

Also Published As

Publication number Publication date
PL2651410T3 (pl) 2021-03-08
HUE027916T2 (en) 2016-11-28
RS54173B1 (en) 2015-12-31
US20200289426A1 (en) 2020-09-17
HRP20150881T1 (hr) 2015-09-25
JP6043296B2 (ja) 2016-12-14
RS61155B1 (sr) 2020-12-31
WO2012080365A1 (de) 2012-06-21
PT2468274E (pt) 2015-09-21
US20140323996A1 (en) 2014-10-30
LT2651410T (lt) 2020-12-28
CA2817461A1 (en) 2012-06-21
CA2817461C (en) 2020-02-25
CN113244199A (zh) 2021-08-13
MY183873A (en) 2021-03-17
SI2651410T1 (sl) 2021-01-29
AU2011343363B2 (en) 2017-06-08
EP2651410B1 (de) 2020-10-14
CA3065240C (en) 2022-02-15
MX2013005581A (es) 2013-08-26
BR112013014616A2 (pt) 2016-09-20
JP2014503523A (ja) 2014-02-13
MX345344B (es) 2017-01-26
PT2651410T (pt) 2020-12-15
AU2011343363A1 (en) 2013-06-20
KR101842309B1 (ko) 2018-03-26
EP2468274A1 (de) 2012-06-27
ES2836483T3 (es) 2021-06-25
SMT201500184B (it) 2015-09-07
EA026520B1 (ru) 2017-04-28
ES2545094T3 (es) 2015-09-08
DK2651410T3 (da) 2020-11-02
ZA201303965B (en) 2014-09-25
KR20130129988A (ko) 2013-11-29
HUE052137T2 (hu) 2021-04-28
AU2017213569A1 (en) 2017-08-31
US10660863B2 (en) 2020-05-26
EP2651410A1 (de) 2013-10-23
CY1116638T1 (el) 2017-03-15
AU2017213569B2 (en) 2019-04-11
PL2468274T3 (pl) 2015-11-30
SI2468274T1 (sl) 2015-10-30
CA3065240A1 (en) 2012-06-21
CN103269698A (zh) 2013-08-28
EA201300704A1 (ru) 2014-01-30
EP2468274B1 (de) 2015-07-01
HK1243336A1 (zh) 2018-07-13
CN103269698B (zh) 2017-07-14
HRP20201880T1 (hr) 2021-02-05
DK2468274T3 (en) 2015-08-31
BR112013014616B1 (pt) 2021-12-21
CN107412202A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
CY1123712T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
BR112012024835A2 (pt) adesivo de distribuição transdérmica
CY1120964T1 (el) Ετερογενη εμφυτευσιμα προϊοντα για χορηγηση φαρμακων
CL2015003377A1 (es) Sistema de liberación transdérmico.
CR20150360A (es) Sistema de liberación transdérmica
UA114101C2 (xx) Трансдермальна терапевтична система для введення фентанілу або його аналога
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
WO2012124966A3 (ko) 펜타닐 경피 패치제
IN2012DN01225A (el)
BR112012001349B8 (pt) processo livre de solvente para produzir uma composição adesiva
WO2012002640A3 (ko) 도네페질을 함유하는 경피흡수제제
AR070031A1 (es) Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas
MX2012008381A (es) Tira dental para administracion de tratamiento oral.
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
AR095258A1 (es) Composiciones transdérmicas de metilfenidato con adhesivos a base de goma
CY1124303T1 (el) Διαδερμικο θεραπευτικο συστημα με καλυπτικη ταινια, που περιλαμβανει δυο συγκολλητικα στρωματα
DE112008002414A5 (de) Reservoirsystem mit verschlossener Membran
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
DOP2014000171A (es) Sistema para la administración de fármacos
TN2015000037A1 (en) Transdermal formulation containing cox inhibitors
WO2016149077A3 (en) Fentanyl transdermal delivery system
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
EA201391023A1 (ru) Способ снижения боли у животных семейства собачьих с помощью трансдермального раствора фентанила
CY1119228T1 (el) Ιατρικα δραστικο εμπλαστρο
DK2257254T3 (da) Plaster